These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 26686245)
1. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells. Chang E; Ganguly S; Rajkhowa T; Gocke CD; Levis M; Konig H Leukemia; 2016 May; 30(5):1025-32. PubMed ID: 26686245 [TBL] [Abstract][Full Text] [Related]
2. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029 [TBL] [Abstract][Full Text] [Related]
4. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia. Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312 [TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014 [TBL] [Abstract][Full Text] [Related]
6. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells. Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830 [TBL] [Abstract][Full Text] [Related]
7. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388 [TBL] [Abstract][Full Text] [Related]
8. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689 [TBL] [Abstract][Full Text] [Related]
9. Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells. Hieber C; Mustafa AM; Neuroth S; Henninger S; Wollscheid HP; Zabkiewicz J; Lazenby M; Alvares C; Mahboobi S; Butter F; Brenner W; Bros M; Krämer OH Biomed Pharmacother; 2024 Aug; 177():117076. PubMed ID: 38971011 [TBL] [Abstract][Full Text] [Related]
10. Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro. Heidel F; Lipka DB; Mirea FK; Mahboobi S; Grundler R; Kancha RK; Duyster J; Naumann M; Huber C; Böhmer FD; Fischer T Br J Haematol; 2009 Mar; 144(6):865-74. PubMed ID: 19183186 [TBL] [Abstract][Full Text] [Related]
11. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792 [TBL] [Abstract][Full Text] [Related]
12. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090 [TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840 [TBL] [Abstract][Full Text] [Related]
14. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways. Wu M; Li L; Hamaker M; Small D; Duffield AS Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911 [TBL] [Abstract][Full Text] [Related]
15. Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia. Kim HJ; Ryu H; Choi HK; Song JY; Hwang SG; Ahn J Anticancer Res; 2021 Feb; 41(2):731-737. PubMed ID: 33517277 [TBL] [Abstract][Full Text] [Related]
16. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472 [TBL] [Abstract][Full Text] [Related]
17. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine. Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965 [TBL] [Abstract][Full Text] [Related]
18. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456 [TBL] [Abstract][Full Text] [Related]
19. NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987 [TBL] [Abstract][Full Text] [Related]
20. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]